Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2020, 164(3):217-225 | DOI: 10.5507/bp.2020.033

Multiple sclerosis and COVID-19

Jan Maresa, Hans-Peter Hartungb
a Department of Neurology, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic
b Klinik fuer Neurologie, Heinrich-Heine Universitaet Duesseldorf, Germany

This paper reviews currently available data on the novel coronavirus and clinical features of COVID-19, followed by a detailed section on possible modifications of immunomodulatory therapy in multiple sclerosis patients with COVID-19, based on what we know so far. There are discussed: (i) The COVID-19 disease (Epidemiological background SARS-CoV-1 coronavirus; Autoimmune response to COVID-19; Asymptomatic course; SARS-CoV-2 test; COVID-19 symptoms), (ii) Treatment of COVID-19 (Experimental plasma treatment; Antiviral therapy; Antimalarial treatment scheme; Biological treatment; Corticosteroid treatment; Symptomatic treatment; Vaccine preparation) and (iii) Multiple sclerosis and SARS-CoV-2 infection (Epidemiological recommendation).

Keywords: coronavirus, COVID-19, multiple sclerosis, immunomodulatory therapy

Received: July 9, 2020; Revised: July 15, 2020; Accepted: July 15, 2020; Prepublished online: July 17, 2020; Published: September 17, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Mares, J., & Hartung, H. (2020). Multiple sclerosis and COVID-19. Biomedical papers, 164(3), 217-225. doi: 10.5507/bp.2020.033
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. WHO. Coronavirus Disease (COVID-19). Situation report, 102. 2020 [cited 2020 Aug 12]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200501-covid-19-sitrep.pdf?sfvrsn=742f4a18_4
    2. Wu F, Zhao S, Yu B, Chen YM, Wan W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, YUan ML, Zhang YL, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes EC, Zhang YZ. A new coronavirus associated with human respiratory disease in China. Nature 2020;579,265-9. Go to original source... Go to PubMed...
    3. Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten Ch, Gulyaeva AA, Haagmans BL, Lauber Ch, Leontovich AM, Neuman BW, Penzar D, Perlman S, Poon LM, Samborskiy D, Sidorov IA, Sola I, Ziebuhr J. Sebere acute respiratory syndrome-related coronavirus. The species and its viruses - a statement of the Coronavirus Study Group. Nature Microbiology 2020;5(4):536-44. doi: 10.1038/s41564-020-0695-z Go to original source... Go to PubMed...
    4. Yuen KS, Ye ZW, Fung SY, Chan CHP, Jin DY. SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci 2020;10:40. doi: 10.1186/s13578-020-00404-4 Go to original source... Go to PubMed...
    5. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, Si HR, Zhu Y, Li B, Huang ChL, Chen HD, Chen J, Luo Y, Guo H, Jiang RD, Chen Y, Shen XR, Wang X, Theng XS, Zhao K, CHen QJ, Deng F, Liu LL, Yan B, Zhan FX, Wang YY, Xiao GF, Shi ZL. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579(7798):270-3. Go to original source... Go to PubMed...
    6. Sherren A, Suliman K, Kazmi A, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020;24,91-8. doi: 10.1016/j.jare.2020.03.005 Go to original source... Go to PubMed...
    7. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, Meng J, Zhu Z, Zhang Z, Wang J, Sheng J, Quan L, Xia Z, Tan W, Cheng G, Jian T. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 2020;27(3),325-8. doi: 10.1016/j.chom.2020.02.001 Go to original source... Go to PubMed...
    8. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med 2020;26:450-2. Go to original source... Go to PubMed...
    9. Weise E. 8 strains of the coronavirus are circling the globe. Here's what clues they're giving scientists. USA Today. 2020 Mar [cited 2020 Aug 12]. Available from: https://eu.usatoday.com/story/news/nation/2020/03/27/scientists-track-coronavirus-strains-mutation/5080571002/.
    10. Nextrain team. Genomic epidemiology of novel coronavirus - Global subsampling. 2020 [cited 2020 Aug 12]. Available from: https://nextstrain.org/ncov/global?m=div
    11. American Chemical Society. Missing link in coronavirus jump from bats to humans could be pangolins, not snakes. 2020 March [cited 2020 Aug 12]. Available from: https://medicalxpress.com/news/2020-03-link-coronavirus-humans-pangolins-snakes.html
    12. Scarborough R. China knew for years bats caused disease, yet left wild animal markets open. The Washington Times. 2020 Mar [cited 2020 Aug 12]. Available from: https://www.washingtontimes.com/news/2020/mar/18/china-knew-years-bats-caused-disease-yet-left-wild/
    13. Taylor A. Experts debunk fringe theory linking China's coronavirus to weapons research. The Washington Post. 2020 Jan [cited 2020 Aug 12]. Available from: https://www.washingtonpost.com/world/2020/01/29/experts-debunk-fringe-theory-linking-chinas-coronavirus-weapons-research/
    14. Cyranoski D. Bat cave solves mystery of deadly SARS virus - and suggests new outbreak could occur. Nature 2017;552(7683):15-16. Go to original source...
    15. Menachery VD, Yount BL, Debbink K, Agnihothram S, Gralinski LE, Plante JA, Graham RL, Scobey T, Ge X, Donaldson EF, Randell SH, Lanzavecchia A, Marasco WA, Shi Z, Baric RS. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med 2015;21(12):1508-13. Go to original source... Go to PubMed...
    16. Botao X, Xiao L. The possible origins of 2019-nCoV coronavirus. Research Gate. 2020 Feb [cited 2020 Aug 12]. Available from https://web.archive.org/web/20200214144447/; https:/www.researchgate.net/publication/339070128_The_possible_origins_of_2019-nCoV_coronavirus
    17. Qiu, J. How China's "Bat Woman" Hunted Down Viruses from SARS to the New Coronavirus. Scientific American. 2020 June [cited 2020 Aug 12]. Available from: https://www.scientificamerican.com/article/how-chinas-bat-woman-hunted-down-viruses-from-sars-to-the-new-coronavirus1/
    18. Diao B, Wang Ch, Tan Y, Chen X, Liu Y, Ning L, Chen L, Li M, Liu Y, Wang G, Yuan Z, Feng Z, Zhang Y, Wu Y, Chen Y. Reduction and Functional Exhaustion of T Cells in Patients with Coronavirus Disease 2019 (COVID-19). Front Immunol 2020;11:827. Go to original source... Go to PubMed...
    19. Herold T, Jurinovic V, Arnreich Ch,Hellmuth JC, von Bergwelt-Baildon M, Klein M, Weinberger T. Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients. 2020;146(1):128-36.doi: 10.1016/j.jaci.2020.05.008 Go to original source... Go to PubMed...
    20. Dahm T, Rudolph H, Schwerk Ch, Schroten H, Tenenbaum T. Neuroinvasion and Inflammation in Viral Central Nervous System Infections. 2016;2016:8562805. doi: 10.1155/2016/8562805 Go to original source... Go to PubMed...
    21. Wadman M, Couzin-Frankel J, Matacic C. How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes. Science 2020 Apr [cited 2020 Aug 12]. Available from: https://www.sciencemag.org/news/2020/04/how-does-coronavirus-kill-clinicians-trace-ferocious-rampage-through-body-brain-toes Go to original source...
    22. Jin H, Hong C, Chen S, Zhou Y. Wang Y, Mao L, Li Y, He Q, Li M, Su Y, Wang D, Wang L, Hu B. Consensus for prevention and management of coronavirus disease 2019 (COVID-19) for neurologists. Stroke Vasc Neurol 2020;5(2):146-51. Go to original source... Go to PubMed...
    23. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung S-M, Hayashi K, Kinoshita R, Yang Y, Yuan B, Akhmetzhanov AR, Linton NM. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis 2020;94:154-5. Go to original source... Go to PubMed...
    24. Khaliq R. China begins publishing COVID-19 asymptomatic cases. Anadolu Agency. 2020 Apr [cited 2020 Aug 12]. Available from: https://www.aa.com.tr/en/asia-pacific/china-begins-publishing-covid-19-asymptomatic-cases/1788213
    25. Baker S. South Korea says recovered coronavirus patients who tested positive again did not relapse: Tests picked up 'dead virus fragments'. Business Insider. 2020 Apr [cited 2020 Aug 12]. Available from: https://www.businessinsider.com/coronavirus-south-korean-reactivated-cases-not-reinfected-experts-2020-4
    26. Xiao SY, Wu Y, Li J. Evolving status of the 2019 novel coronavirus infections: proposal of conventional serologic assays for disease diagnostics and infection monitoring. J Med Virol 2020;92(5):464-7. doi: 10.1002/jmv.25702 Go to original source... Go to PubMed...
    27. WHO. Laboratory testing strategy recommendations for COVID-19 interim guidance. 2020 [cited 2020 Aug 12]. Available from: https://www.who.int/publications-detail/laboratory-testing-strategy-recommendations-for-covid-19-interim-guidance
    28. WikiProjekt SARS-CoV-2. Covid-19. Wikipedia. 2020. [cited 2020 Aug 12]. Available from: https://cs.wikipedia.org/wiki/Covid-19
    29. Cha AE. A mysterious blood-clotting complication is killing coronavirus patients. (2020). The Washington Post. 2020 Apr [cited 2020 Aug 12]. Available from: https://www.washingtonpost.com/health/2020/04/22/coronavirus-blood-clots/
    30. WHO. Q&A on coronaviruses (COVID-19). 2020 [cited 2020 Aug 12]. Available from: https://www.who.int/news-room/q-a-detail/q-a-coronaviruses
    31. ČTK. Koronavirus se může ohlásit ztrátou čichu a chuti. Novinky. 2020 March [cited 2020 Aug 12]. Available from: https://www.novinky.cz/koronavirus/clanek/koronavirus-se-muze-ohlasit-ztratou-cichu-a-chuti-40317693
    32. Covidové prsty mohou být prvním i jediným příznakem koronaviru. iDNES. 2020 May [cited 2020 Aug 12]. Available from: https://www.idnes.cz/zpravy/domaci/covidove-prsty-koronavirus-priznak-nakazy-vyrazka-vinohradska-nemocnice-deti-mladistvi.A200504_113414_domaci_kane
    33. SÚKL. Přehled hodnocených léčiv na nemoc COVID-19. 2020 Jun [cited 2020 Aug 12]. Available from: http://www.sukl.cz/sukl/prehled-hodnocenych-leciv-na-nemoc-covid-19
    34. Sterling T, Irwin JJ. ZINC 15 - Ligand Discovery for Everyone. J Chem Inf Mod 2015; 55(11):2324-37. Go to original source... Go to PubMed...
    35. Treatments for COVID-19. Harvard Health Publishing. 2020 Apr [cited 2020 Aug 12]. Available from: https://www.health.harvard.edu/diseases-and-conditions/treatments-for-covid-19
    36. Grifols Announces Formal Collaboration with US Government to Produce the First Treatment Specifically Targeting COVID-19. Grifols. 2020 Mar [cited 2020 Aug 12]. Available from: https://www.grifols.com/en/view-news/-/news/grifols-announces-formal-collaboration-with-us-government-to-produce-the-first-treatment-specifically-targeting-covid-19
    37. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang Ch, Mei Ch, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Haden FG, Horby PW, Cao B, Wang C. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020;395(10236), P1569-1578. doi: 10.1016/S0140-6736(20)31022-9. Go to original source... Go to PubMed...
    38. Science News. First randomized trial of Remdesivir suggests antiviral drug is not associated with significant clinical benefits, more research needed. Science News. 2020 Apr [cited 2020 Aug 12]. Available from: https://www.sciencedaily.com/releases/2020/04/200429134020.htm
    39. Hennigan S, Kavanaugh A Interleukin-6 inhibitors in the treatment of rheumatoid arthritis. Ther Clin Risk Manag 2008;4(4):767-75. Go to original source... Go to PubMed...
    40. Swedish Orphan Biovitrum. A Phase 2/3, Randomized, Open-label, Parallel Group, 3-arm, Multicenter Study Investigating the Efficacy and Safety of Intravenous Administrations of Emapalumab, an Anti-interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and Anakinra, an Interleukin-1(IL-1) Receptor Antagonist, Versus Standard of Care, in Reducing Hyper-inflammation and Respiratory Distress in Patients With SARS-CoV-2 Infection. 2020 Apr [cited 2020 Aug 12]. Available from: https://clinicaltrials.gov/ct2/show/NCT04324021
    41. Assistance Publique - Hôpitaux de Paris. Cohort Multiple randomized controlled trials open-label of immune modulatory drugs and other treatments in COVID-19 patients. EU Clinical trials register. 2020 [cited 2020 Aug 12]. Available from:https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001246-18
    42. InflaRx GmbH. A pragmatic adaptive open label, randomized Phase II/III multicenter study of IFX-1 in Patients with severe COVID-19 Pneumonia - "PANAMO". EU Clinical trials register. 2020 [cited 2020 Aug 12]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/search?query=2020-001335-28
    43. Cytodyn. Severely Ill COVID-19 Patient at Leading Southern California Medical Center Extubated Three Days After Treatment with CytoDyn's Leronlimab; Two Moderate COVID-19 Patients Removed from External Oxygen Following One Day of Treatment with Leronlimab and Discharged from Hospital. 2020 Apr [cited 2020 Aug 12]. Available from: https://www.cytodyn.com/newsroom/press-releases/detail/412/severely-ill-covid-19-patient-at-leading-southern
    44. Belgium - FPS Health-DGM. A prospective, randomized, factorial design, interventional study to compare the safety and efficacy of combinations of blockade of interleukin-6 pathway and interleukin-1 pathway to best standard of care in improving oxygenation and short- and long-term outcome of COVID-19 patients with acute hypoxic respiratory failure and systemic cytokine release syndrome. EU Clinical trials register. 2020 [cited 2020 Aug 12]. Available from: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001500-41/BE
    45. Russel B, Moss C, Rigg A, Hemelrijck, M. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Ecancermedicalscience 2020;14:1023. doi: 10.3332/ecancer.2020.1023 Go to original source... Go to PubMed...
    46. University of Oxford. Recovery. Randomised evaluation of COVID-19 Therapy. 2020 [cited 2020 Aug 12]. Available from: https://www.recoverytrial.net/
    47. RTDS Verein, Engl. RTDS Asscociation. Exploration of safety, tolerability and clinical efficacy of Solnatide IMP in patients infected with the 2019 new coronavirus. Cordis EU research results. 2020 Apr [cited 2020 Aug 12]. Available from: https://cordis.europa.eu/project/id/101003595
    48. Baumann Kreuziger L, Lee A, Garcia D, Cuker A, Cushman M, DeSancho M, Connors M. COVID-19 and VTE/Anticoagulation: Frequently Asked Questions. American Society of Hematology. 2020 June [cited 2020 Aug 12]. Available from: https://www.hematology.org/covid-19/covid-19-and-vte-anticoagulation.
    49. Caly L, Druce DD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Research 2020;178:1-4. Go to original source... Go to PubMed...
    50. Zhang MY, Choudhry V, Xiao X, Dimitrov D. Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS. Cur Opin Mol Ther 2005;7(2):151-6.
    51. Kekrt L. Imunizace proti koronaviru není stoprocentní. Je možné se nakazit opětovně. Czech Sight. 2020 Feb [cited 2020 Aug 12]. Available from: https://www.czechsight.cz/imunizace-proti-koronaviru-neni-stoprocentni-je-mozne-se-nakazit-opetovne/
    52. First Clinical Trial of a COVID-19 Vaccine Authorised in Germany. Paul Ehrlich Institute. 2020 Aug [cited 2020 Aug 12]. Available from: https://www.pei.de/EN/newsroom/press-releases/year/2020/08-first-clinical-trial-sars-cov-2-germany.html
    53. Chen S. Coronavirus: low antibody levels raise questions about reinfection risk. South China Morning Post. 2020 Apr [cited 2020 Aug 12]. Available from: https://www.scmp.com/news/china/science/article/3078840/coronavirus-low-antibody-levels-raise-questions-about
    54. Neurologická sekce ČSL JEP. Odborná doporučení Neuroimunologické sekce ČLS JEP pro pacienty s roztroušenou sklerózou v době epidemie COVID-19. Aktivní život. 2020 [cited 2020 Aug 12]. Available from: http://aktivnizivot.cz/2020/03/17/odborna-doporuceni-neuroimunologicke-sekce-cls-jep-pro-pacienty-s-roztrousenou-sklerozou-v-dobe-epidemie-covid-19
    55. MS Trust. Coronavirus, Covid-19 and multiple sclerosis. 2020 [cited 2020 Aug 12]. Available from: https://www.mstrust.org.uk/a-z/coronavirus-covid-19-and-multiple-sclerosis.
    56. MS Ireland. COVID-19 and MS. 2020 May [cited 2020 Aug 12]. Available from: https://www.ms-society.ie/covid-19-and-ms
    57. Can the coronavirus really live for 3 days on plastic? Yes, but it's complicated. Medical Xpress. 2020 Mar [cited 2020 Aug 12]. Available from: https://medicalxpress.com/news/2020-03-coronavirus-days-plastic-complicated.html
    58. Van Doremalen N, Bushmaker T, Morris DH, Gamble A, Williamson BN, Tamin A, Harcourt JL, Thornburg NJ, Gerber SI, Lloyd-Smith JO, de Wit E. Aerosol and Surfase Stability of SARS-CoV-2 as Compared with SARS-CoV-1. NEJM 2020;382:1564-7. Go to original source... Go to PubMed...
    59. Giovannoni G, Hawkes Ch, Lechner-Scott J, Levy M, Waubant E, Gold J. The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord 2020;39:102073. Go to original source... Go to PubMed...
    60. Souhrn údajů o přípravku Tysabri. 2020 Apr [cited 2020 Aug 12]. Available from: https://www.biogen.com.cz/content/dam/corporate/cs_CZ/pdfs/Products/VPOIS-Tysabri-300-mg-inf-cnc-sol-SPC-04-2018.pdf

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content